Sinovac Biotech [SVA] vs Teradata [TDC] Detailed Stock Comparison
Sinovac Biotech
NASDAQ
Loading...
Teradata
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sinovac Biotech wins in 8 metrics, Teradata wins in 9 metrics, with 0 ties. Teradata appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sinovac Biotech | Teradata | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 6.66 | 18.65 | Sinovac Biotech |
| Price-to-Book Ratio | 0.05 | 11.34 | Sinovac Biotech |
| Debt-to-Equity Ratio | 0.02 | 331.25 | Sinovac Biotech |
| PEG Ratio | 0.02 | -0.24 | Teradata |
| EV/EBITDA | -4.52 | 7.99 | Sinovac Biotech |
| Profit Margin (TTM) | 59.51% | 6.57% | Sinovac Biotech |
| Operating Margin (TTM) | -33.63% | 5.88% | Teradata |
| EBITDA Margin (TTM) | N/A | 5.88% | N/A |
| Return on Equity | -0.88% | 87.65% | Teradata |
| Return on Assets (TTM) | -0.78% | 7.03% | Teradata |
| Free Cash Flow (TTM) | $-41.69M | $277.00M | Teradata |
| Dividend Yield | 1,700.15% | N/A | N/A |
| 1-Year Return | 0.00% | -24.92% | Sinovac Biotech |
| Price-to-Sales Ratio (TTM) | 1.43 | 1.19 | Teradata |
| Enterprise Value | $-328.71M | $2.21B | Teradata |
| EV/Revenue Ratio | -0.73 | 1.32 | Sinovac Biotech |
| Gross Profit Margin (TTM) | 86.71% | 56.37% | Sinovac Biotech |
| Revenue per Share (TTM) | $5 | $18 | Teradata |
| Earnings per Share (Diluted) | $-1.06 | $1.13 | Teradata |
| Beta (Stock Volatility) | N/A | 0.83 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sinovac Biotech vs Teradata Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Teradata | -0.61% | 2.42% | -1.95% | -6.80% | -13.41% | -31.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 15.95% | 71.16% | 75.34% |
| Teradata | -24.92% | -36.73% | -14.25% | -28.38% | -34.94% | -22.21% |
Performance & Financial Health Analysis: Sinovac Biotech vs Teradata
| Metric | SVA | TDC |
|---|---|---|
| Market Information | ||
| Market Cap | $642.44M | $1.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | N/A | 1,253,370 |
| 90 Day Avg. Volume | N/A | 1,035,960 |
| Last Close | $6.47 | $21.12 |
| 52 Week Range | $6.47 - $6.47 | $18.43 - $33.69 |
| % from 52W High | 0.00% | -37.31% |
| All-Time High | $12.50 (Aug 31, 2009) | $80.97 (Sep 03, 2012) |
| % from All-Time High | -48.24% | -73.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 1.84% | -0.06% |
| Quarterly Earnings Growth | 3.04% | -0.76% |
| Financial Health | ||
| Profit Margin (TTM) | 0.60% | 0.07% |
| Operating Margin (TTM) | -0.34% | 0.06% |
| Return on Equity (TTM) | -0.01% | 0.88% |
| Debt to Equity (MRQ) | 0.02 | 331.25 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $121.57 | $1.86 |
| Cash per Share (MRQ) | N/A | $3.91 |
| Operating Cash Flow (TTM) | $113.55M | $284.00M |
| Levered Free Cash Flow (TTM) | $-105,900,000 | $266.25M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1,700.15% | N/A |
| Last 12-Month Dividend | $110.00 | N/A |
Valuation & Enterprise Metrics Analysis: Sinovac Biotech vs Teradata
| Metric | SVA | TDC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 6.66 | 18.65 |
| Forward P/E | -53.92 | 8.57 |
| PEG Ratio | 0.02 | -0.24 |
| Price to Sales (TTM) | 1.43 | 1.19 |
| Price to Book (MRQ) | 0.05 | 11.34 |
| Market Capitalization | ||
| Market Capitalization | $642.44M | $1.99B |
| Enterprise Value | $-328,711,264 | $2.21B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.73 | 1.32 |
| Enterprise to EBITDA | -4.52 | 7.99 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.83 |
| Book Value per Share (MRQ) | $121.57 | $1.86 |
Financial Statements Comparison: Sinovac Biotech vs Teradata
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SVA | TDC |
|---|---|---|
| Revenue/Sales | $327.45M | $418.00M |
| Cost of Goods Sold | $43.53M | $170.00M |
| Gross Profit | $283.93M | $248.00M |
| Research & Development | $2.66M | $66.00M |
| Operating Income (EBIT) | $197.04M | $66.00M |
| EBITDA | $200.07M | $85.00M |
| Pre-Tax Income | $198.37M | $58.00M |
| Income Tax | $25.67M | $14.00M |
| Net Income (Profit) | $172.70M | $44.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SVA | TDC |
|---|---|---|
| Cash & Equivalents | $1.27B | $368.00M |
| Total Current Assets | $11.83B | $791.00M |
| Total Current Liabilities | $1.15B | $946.00M |
| Long-Term Debt | $217.09M | $497.00M |
| Total Shareholders Equity | $12.02B | $158.00M |
| Retained Earnings | $7.12B | $-1.91B |
| Property, Plant & Equipment | $45.53M | $209.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SVA | TDC |
|---|---|---|
| Operating Cash Flow | $455.16M | $38.00M |
| Capital Expenditures | $-57.70M | N/A |
| Free Cash Flow | $423.23M | $7.00M |
| Debt Repayment | $-6.58M | $-22.00M |
| Common Stock Repurchase | N/A | $-44.00M |
Short Interest & Institutional Ownership Analysis
| Metric | SVA | TDC |
|---|---|---|
| Shares Short | N/A | 6.59M |
| Short Ratio | N/A | 6.95 |
| Short % of Float | N/A | 0.10% |
| Average Daily Volume (10 Day) | N/A | 1,253,370 |
| Average Daily Volume (90 Day) | N/A | 1,035,960 |
| Shares Outstanding | 99.64M | 95.10M |
| Float Shares | N/A | 83.97M |
| % Held by Insiders | N/A | 0.02% |
| % Held by Institutions | N/A | 1.01% |
Dividend Analysis & Yield Comparison: Sinovac Biotech vs Teradata
| Metric | SVA | TDC |
|---|---|---|
| Last 12-Month Dividend | $110.00 | N/A |
| Last 12-Month Dividend Yield | 1,700.15% | N/A |
| 3-Year Avg Annual Dividend | $36.67 | N/A |
| 3-Year Avg Dividend Yield | 850.08% | N/A |
| 3-Year Total Dividends | $110.00 | N/A |
| Ex-Dividend Date | Jul 10, 2025 | N/A |